Piper Sandler Reiterates Overweight Rating on Madrigal Pharmaceuticals (MDGL)
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $336.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
